Treating malaria: new drugs for a new era

12 Sep 2017

Dennis Shanks, Jörg J Möhrle

The Lancet Infectious Diseases

DOI: 10.1016/S1473-3099(17)30475-9

In The Lancet Infectious Diseases, Ousmane Koita and colleagues reported the results of a randomised, phase 2, non-inferiority clinical trial. They compared AQ-13, a next generation 4-aminoquinoline (4-AQ) compound, with artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in 66 Malian men.

Read the full article on The Lancet's website.